Exact Sciences' Shares Take a Hit Following Colorectal Cancer Dx Presentation | GenomeWeb

By Tony Fong

NEW YORK (GenomeWeb News) – Shares of Exact Sciences tumbled 20 percent on Friday, a day after the firm reported validation study results on its stool-based DNA colorectal cancer screening test.

The firm reported that the test had a sensitivity of 64 percent for pre-cancerous lesions and 85 percent for cancerous lesions and a specificity of 88 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.